The estimated Net Worth of Robert O Hopkins is at least $1.63 Million dollars as of 21 February 2021. Mr. Hopkins owns over 22,258 units of Adamis Pharmaceuticals Corp stock worth over $213,342 and over the last 14 years he sold ADMP stock worth over $98,624. In addition, he makes $1,313,350 as Chief Financial Officer and Senior Vice President - Finance at Adamis Pharmaceuticals Corp.
Robert has made over 12 trades of the Adamis Pharmaceuticals Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 22,258 units of ADMP stock worth $17,139 on 21 February 2021.
The largest trade he's ever made was selling 35,000 units of Adamis Pharmaceuticals Corp stock on 20 November 2020 worth over $14,350. On average, Robert trades about 6,105 units every 29 days since 2010. As of 21 February 2021 he still owns at least 277,067 units of Adamis Pharmaceuticals Corp stock.
You can see the complete history of Mr. Hopkins stock trades at the bottom of the page.
Robert O. Hopkins serves as Chief Financial Officer, Senior Vice President - Finance of the Company. Mr. Hopkins became Vice President, Finance and Chief Financial Officer of the Company in April 2009 in connection with the closing of the merger transaction between the Company and Old Adamis. He joined Old Adamis in April 2007 as Vice President, Finance and Chief Financial Officer. From 2000 to 2004, he was an Executive Vice President and the Chief Financial Officer of Chatham Capital Corp. In that position he managed financial operations for a corporation that held several hospitals, an extensive life sciences operation and a number of other business units within its portfolio. Mr. Hopkins served as Chief Financial Officer of Veritel Corp. from 1999 and 2000, a biometric software company. He has also served as Chief Operating Officer for Circle Trust Company from 2004 to 2005, during which time he was responsible for corporate reorganization after acquiring a troubled trust company. From 2005 until Mr. Hopkins joined Old Adamis in April 2007, he consulted for Acumen Enterprises providing analysis and business plans for the various projects with which the company was involved. From 1997 to 1999, Mr. Hopkins was Senior Vice President for Finance for the Mariner Post-Acute Network, Atlanta, Georgia. In this position he was responsible for financial management of a division consisting of 12 long-term, acute care hospitals. Among his previous medical-related experience, he has served as Assistant Administrator of Finance for Kindred Hospitals; President and Chief Executive Officer of Doctors Hospital of Hyde Park; and Vice President of Accounting for Cancer Treatment Centers of America. Mr. Hopkins received a B.S. degree in Finance from Indiana State University and an M.B.A. from Lake Forest Graduate School of Management.
As the Chief Financial Officer and Senior Vice President - Finance of Adamis Pharmaceuticals Corp, the total compensation of Robert Hopkins at Adamis Pharmaceuticals Corp is $1,313,350. There are 2 executives at Adamis Pharmaceuticals Corp getting paid more, with Dennis Carlo having the highest compensation of $1,770,310.
Robert Hopkins is 60, he's been the Chief Financial Officer and Senior Vice President - Finance of Adamis Pharmaceuticals Corp since 2018. There are 8 older and 3 younger executives at Adamis Pharmaceuticals Corp. The oldest executive at Adamis Pharmaceuticals Corp is Dr. Dennis J. Carlo, 78, who is the Pres, CEO & Director.
Robert's mailing address filed with the SEC is C/O ADAMIS PHARMACEUTICALS CORPORATION, 11682 EL CAMINO REAL, STE 300, SAN DIEGO, CA, 92130.
Over the last 14 years, insiders at Adamis Pharmaceuticals Corp have traded over $2,051,720 worth of Adamis Pharmaceuticals Corp stock and bought 87,550 units worth $188,843 . The most active insiders traders include Ahmed Shayan Fazlur Eses Ho..., Dennis J Phd Carlo, and David J. Marguglio. On average, Adamis Pharmaceuticals Corp executives and independent directors trade stock every 34 days with the average trade being worth of $12,919. The most recent stock trade was executed by Dennis J Phd Carlo on 25 May 2022, trading 250,000 units of ADMP stock currently worth $192,500.
adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
Adamis Pharmaceuticals Corp executives and other stock owners filed with the SEC include: